Loading
Life sciences · Journal article
BMC Endocrine Disorders · October 15, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Introduction Low total testosterone in men is associated with adverse metabolic health, but population-based data from Central Asia remain limited. Aim To estimate the prevalence of biochemically low total testosterone and examine its anthropometric, sociodemographic, behavioral, and metabolic correlates among men in Kazakhstan. Methods We conducted a cross-sectional analysis of a national WHO STEPS survey performed in Kazakhstan from May to October 2025. Among 3,198 eligible men aged 18–69 years, 3,083 had total testosterone measurements suitable for analysis. Survey weights, stratification, and clustering were incorporated in design-based analyses. The primary outcome was total testosterone <8 nmol/L; thresholds of <10 and <12 nmol/L were examined in sensitivity analyses. The primary logistic model included age, BMI, and HbA1c; total testosterone was also analysed continuously after logarithmic transformation. Results The observed proportion with total testosterone <8 nmol/L was 5.1% (156/3,083), and the survey-weighted prevalence was 5.3% (95% CI 4.4–6.2%). In the primary model (n=2,959), overweight (aOR 2.05, 95% CI 1.15–3.64), obesity (aOR 4.58, 95% CI 2.41–8.69), prediabetes-range HbA1c (aOR 2.39, 95% CI 1.49–3.82), and diabetes-range HbA1c (aOR 3.49, 95% CI 1.91–6.38) were associated with low testosterone. For men aged 60–69 versus 18–29 years, the age-only OR was 1.84 (95% CI 1.03–3.29), whereas after adjustment for BMI and HbA1c the aOR was 0.65 (95% CI 0.31–1.36). In continuous models, overweight and obesity were associated with 15.0% and 24.8% lower testosterone, respectively; prediabetes-range and diabetes-range HbA1c were associated with 19.0% and 24.5% lower testosterone. Associations with obesity and dysglycemia remained positive using the <10 and <12 nmol/L thresholds. Conclusion In men aged 18–69 years participating in a national WHO STEPS survey, biochemically low total testosterone was consistently associated with excess adiposity and HbA1c-defined dysglycemia. The age association changed direction after metabolic adjustment and was not statistically significant. These findings describe biochemical associations and should not be interpreted as a diagnosis of clinical hypogonadism. Registration Clinical trials gov identifier NCT06953180; registered May 1, 2025.